1. Cytotoxicity of tranexamic acid to tendon and bone in vitro: Is there a safe dosage?
- Author
-
Scott M. Bolam, Arama O’Regan-Brown, Subhajit Konar, Karen E. Callon, Brendan Coleman, Nicola Dalbeth, A. Paul Monk, David S. Musson, Jillian Cornish, and Jacob T. Munro
- Subjects
Arthroscopy ,Intra-articular drugs ,Tranexamic acid ,Toxicity ,Orthopaedics ,Peri-articular tissues ,Orthopedic surgery ,RD701-811 ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Introduction Tranexamic acid (TXA) has been shown to be effective at reducing peri-operative blood loss and haemarthrosis in arthroplasty and arthroscopic soft tissue reconstructions. Intra-articular application, as an injection or peri-articular wash, is becoming increasingly common. Recent studies have shown TXA has the potential to be cytotoxic to cartilage, but its effects on human tendon and bone remain poorly understood. The aim of this study was to investigate whether TXA has any detrimental effects on tendon-derived cells and osteoblast-like cells and determine whether there is a safe dosage for clinical application. Materials and methods Primary tendon-derived cells and osteoblast-like cells were harvested from hamstring tendons and trabecular bone explants, respectively, and analysed in vitro with a range of TXA concentrations (0 to 100 mg/ml) at time points: 3 and 24 h. The in vitro toxic effect of TXA was investigated using viability assays (alamarBlue), functional assays (collagen deposition), fluorescent microscopy and live/apoptosis/necrosis staining for cell death mechanisms in 2D monolayer and 3D collagen gel cell culture. Results There was a significant (P 35 mg/ml resulted in significantly (P
- Published
- 2022
- Full Text
- View/download PDF